Drug Index


Mechanism :

Inhibits bacterial protein synthesis by binding to different sites on the 50S bacterial ribosomal subunit thereby inhibiting protein synthesis.

Indication :

  • Treatment of complicated skin and skin structure infections caused by methicillin susceptible Staphylococcus aureus or Streptococcus pyogenes.
  • Off-label:
  • MRSA bacteremia
  • MRSA and MDR Enterococcus faecium infective endocarditis

Contraindications :

Hypersensitivity to quinupristin, dalfopristin, other streptogramins (e.g., pristinamycin, virginiamycin), or any component of the formulation.

Dosing :

≥12 years:
7.5 mg/kg IV every 8-12 hours for at least 7 days.

Adverse Effect :

Hyperbilirubinemia, local pain, inflammation, arthralgia, myalgia, thrombophlebitis, skin rash, increased LDH, CPK & GGT, anemia.

Interaction :

Cyclosporine: Quinupristin may increase the serum concentration of Cyclosporine.

Aripiprazole: CYP3A4 Inhibitors may increase the serum concentration of Aripiprazole.

Hepatic Dose :

Effects on liver not studied; pharmacokinetic data suggest adjustment may be necessary.
03/21/2024 00:36:32 Quinupristin/Dalfopristin
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0